Skip to main navigation
Skip to search
Skip to main content
University of Toyama Home
日本語
English
Home
Profiles
Research units
Projects
Research output
Datasets
Prizes
Activities
Courses
Search by expertise, name or affiliation
Supplementary Material for: Lenvatinib as second-line treatment after atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma –clinical results show importance of hepatic reserve function
Atsushi Hiraoka
(Contributor)
Takashi Kumada
(Contributor)
Toshifumi Tada
(Contributor)
Masashi Hirooka
(Contributor)
Kazuya Kariyama
(Contributor)
Joji Tani
(Contributor)
Masanori Atsukawa
(Contributor)
Koichi Takaguchi
(Contributor)
Ei Itobayashi
(Contributor)
Shinya Fukunishi
(Contributor)
Kunihiko Tsuji
(Contributor)
Toru Ishikawa
(Contributor)
Kazuto Tajiri
(Contributor)
Hironori Ochi
(Contributor)
Satoshi Yasuda
(Contributor)
Hidenori Toyoda
(Contributor)
Chikara Ogawa
(Contributor)
Takashi Nishimura
(Contributor)
Takeshi Hatanaka
(Contributor)
Satoru Kakizaki
(Contributor)
Noritomo Shimada
(Contributor)
Kazuhito Kawata
(Contributor)
Atsushi Naganuma
(Contributor)
Hisashi Kosaka
(Contributor)
Tomomitsu Matono
(Contributor)
Hidekatsu Kuroda
(Contributor)
Y. Yata
(Contributor)
Hideko Ohama
(Contributor)
Fujimasa Tada
(Contributor)
Kazuhiro Nouso
(Contributor)
Asahiro Morishita
(Contributor)
Akemi Tsutsui
(Contributor)
Takuya Nagano
(Contributor)
Norio Itokawa
(Contributor)
Tomomi Okubo
(Contributor)
Taeang Arai
(Contributor)
Keisuke Yokohama
(Contributor)
Michitaka Imai
(Contributor)
Yohei Koizumi
(Contributor)
Shinichiro Nakamura
(Contributor)
Hiroko Iijima
(Contributor)
Masaki Kaibori
(Contributor)
Yoichi Hiasa
(Contributor)
Internal Medicine (3)
Dataset
Overview
Research output
(1)
Research output
Research output per year
2023
2023
2023
1
Article
Research output per year
Research output per year
1 results
Publication Year, Title
(descending)
Publication Year, Title
(ascending)
Title
Type
Filter
Article
Search results
2023
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function
On behalf of the Real-Life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
,
2023/10/01
,
In:
Oncology (Switzerland).
101
,
10
,
p. 624-633
10 p.
Research output
:
Contribution to journal
›
Article
›
peer-review
Lenvatinib
100%
Unresectable Hepatocellular Carcinoma
100%
Atezolizumab Plus Bevacizumab
100%
Second-line Treatment
100%
Hepatic Functional Reserve
100%
23
Scopus citations